The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
Authors
Keywords
NSAIDs, Microglia, Tau, Complement, Biomarkers, CSF, Positron emission tomography
Journal
ACTA NEUROPATHOLOGICA
Volume 126, Issue 4, Pages 479-497
Publisher
Springer Nature
Online
2013-09-19
DOI
10.1007/s00401-013-1177-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 2013 Alzheimer's disease facts and figures
- (2013) Alzheimers & Dementia
- Mediterranean Diet, Cognitive Function, and Dementia
- (2013) Ilianna Lourida et al. EPIDEMIOLOGY
- Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive?
- (2013) Haythum O Tayeb et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Tau pathology and neurodegeneration
- (2013) Maria Grazia Spillantini et al. LANCET NEUROLOGY
- Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease
- (2013) A. Prestia et al. NEUROLOGY
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- (2013) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
- (2013) Jon B Toledo et al. Alzheimers Research & Therapy
- Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia
- (2012) Peder Buchhave ARCHIVES OF GENERAL PSYCHIATRY
- Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
- (2012) Henrik Zetterberg ARCHIVES OF NEUROLOGY
- Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
- (2012) Vladimir Coric et al. ARCHIVES OF NEUROLOGY
- The spectrum of disease in chronic traumatic encephalopathy
- (2012) Ann C. McKee et al. BRAIN
- Abeta DNA Vaccination for Alzheimers Disease: Focus on Disease Prevention
- (2012) David H. Cribbs CNS & Neurological Disorders-Drug Targets
- Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
- (2012) Bruno P Imbimbo et al. Expert Review of Clinical Immunology
- Crude caffeine reduces memory impairment and amyloid β1–42 levels in an Alzheimer’s mouse model
- (2012) Yi-Fang Chu et al. FOOD CHEMISTRY
- Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease
- (2012) Sang-Ho Choi et al. JOURNAL OF NEUROCHEMISTRY
- Sting of Alzheimer's failures offset by upcoming prevention trials
- (2012) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Genetic association of CR1 with Alzheimer's disease: A tentative disease mechanism
- (2012) Lili-Naz Hazrati et al. NEUROBIOLOGY OF AGING
- Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex
- (2012) Moonhee Lee et al. NEUROBIOLOGY OF AGING
- Suspected limited efficacy of γ-secretase modulators
- (2012) Nobuto Kakuda et al. NEUROBIOLOGY OF AGING
- CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
- (2012) T. T. Seppala et al. NEUROLOGY
- Vitamin D, cognition, and dementia: A systematic review and meta-analysis
- (2012) C. Balion et al. NEUROLOGY
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
- (2012) Randall J. Bateman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Variant of TREM2 Associated with the Risk of Alzheimer's Disease
- (2012) Thorlakur Jonsson et al. NEW ENGLAND JOURNAL OF MEDICINE
- TREM2 Variants in Alzheimer's Disease
- (2012) Rita Guerreiro et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified γ-Secretase Complexes
- (2012) Matthias Cacquevel et al. PLoS One
- Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Amyloid-beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data
- (2011) Andrei G. Vlassenko et al. ANNALS OF NEUROLOGY
- Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
- (2011) Paul S. Aisen et al. Archives of Medical Science
- Cerebrospinal Fluid Profiles and Prospective Course and Outcome in Patients With Amnestic Mild Cognitive Impairment
- (2011) Ozioma C. Okonkwo ARCHIVES OF NEUROLOGY
- Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease
- (2011) Grazia D'Onofrio et al. Expert Opinion on Drug Discovery
- Complement receptor 1 (CR1) and Alzheimer's disease
- (2011) Helen Crehan et al. IMMUNOBIOLOGY
- Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease
- (2011) Sherry L. La Porte et al. JOURNAL OF MOLECULAR BIOLOGY
- Targets for AD treatment: conflicting messages from γ-secretase inhibitors
- (2011) Kumar Sambamurti et al. JOURNAL OF NEUROCHEMISTRY
- Developing β-secretase inhibitors for treatment of Alzheimer’s disease
- (2011) Arun K. Ghosh et al. JOURNAL OF NEUROCHEMISTRY
- Activation of α-secretase cleavage
- (2011) Rolf Postina JOURNAL OF NEUROCHEMISTRY
- Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?
- (2011) Natalia N. Nalivaeva et al. JOURNAL OF NEUROCHEMISTRY
- Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease
- (2011) Maria I Fonseca et al. Journal of Neuroinflammation
- No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease
- (2011) Antje Hillmann et al. NEUROBIOLOGY OF AGING
- A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
- (2011) S. Salloway et al. NEUROLOGY
- Alzheimer's Disease: The Challenge of the Second Century
- (2011) D. M. Holtzman et al. Science Translational Medicine
- Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study
- (2010) Felix Bermejo-Pareja et al. BMC Neurology
- Alzheimer's disease: clinical trials and drug development
- (2010) Francesca Mangialasche et al. LANCET NEUROLOGY
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
- (2009) Leslie M. Shaw et al. ANNALS OF NEUROLOGY
- A Specific Enzyme-Linked Immunosorbent Assay for Measuring β-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer Disease
- (2009) Weiming Xia et al. ARCHIVES OF NEUROLOGY
- The Perils of Alzheimers Drug Development
- (2009) Lon Schneider et al. Current Alzheimer Research
- Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease
- (2009) David B Henley et al. EXPERT OPINION ON PHARMACOTHERAPY
- Chronic Traumatic Encephalopathy in Athletes: Progressive Tauopathy After Repetitive Head Injury
- (2009) Ann C. McKee et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Docosahexaenoic acid supplementation of primary rat hippocampal neurons attenuates the neurotoxicity induced by aggregated amyloid beta protein42 and up-regulates cytoskeletal protein expression
- (2009) Pao-Yuan Wang et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
- (2009) Pieter Jelle Visser et al. LANCET NEUROLOGY
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
- (2009) Clifford R Jack et al. LANCET NEUROLOGY
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease
- (2009) Denise Harold et al. NATURE GENETICS
- Structure-neurotoxicity relationships of amyloid -protein oligomers
- (2009) K. Ono et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The amyloid cascade hypothesis
- (2008) Amos D. Korczyn Alzheimers & Dementia
- Neprilysin: An Enzyme Candidate to Slow the Progression of Alzheimer's Disease
- (2008) Salim S. El-Amouri et al. AMERICAN JOURNAL OF PATHOLOGY
- Distinct Pools of β-Amyloid in Alzheimer Disease–Affected Brain
- (2008) Joshua R. Steinerman et al. ARCHIVES OF NEUROLOGY
- Preventing β-amyloid fibrillization and deposition: β-sheet breakers and pathological chaperone inhibitors
- (2008) Thomas Wisniewski et al. BMC NEUROSCIENCE
- Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice
- (2008) Ann C. McKee et al. BRAIN RESEARCH
- Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer’s disease
- (2008) Jun Zhou et al. JOURNAL OF NEUROCHEMISTRY
- Ibuprofen modifies cognitive disease progression in an Alzheimer’s mouse model
- (2008) D. Van Dam et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
- (2008) Clive Holmes et al. LANCET
- Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology
- (2008) Z. Arvanitakis et al. NEUROLOGY
- Protective effects of NSAIDs on the development of Alzheimer disease
- (2008) Steven C. Vlad et al. NEUROLOGY
- No advantage of A 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies
- (2008) C. A. Szekely et al. NEUROLOGY
- Amyloid- Dynamics Correlate with Neurological Status in the Injured Human Brain
- (2008) D. L. Brody et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More